Generalized Myasthenia Gravis
📧 Sign up to get email alerts when something new happens for Generalized Myasthenia Gravis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-02-16Clinical Trial Update: An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis [Phase 2]
Extension study of MOM-M281-004 (M281) in generalized myasthenia gravis terminated; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-02-08Clinical Trial Update: An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness [Phase 3]
Phase 3 trial update on ARGX-113 for generalized myasthenia gravis reports completed results.
-
CLINICAL_TRIALS trial_result · 2021-10-27Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis [Phase 2]
Phase 2 clinical trial evaluating safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of M281 in adults with generalized m…
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis [Phase 3]
Phase 3 extension study assessing safety and efficacy of eculizumab in refractory generalized myasthenia gravis has completed with results p…
-
CLINICAL_TRIALS trial_result · 2018-02-07Clinical Trial Update: Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) [Phase 3]
Phase 3 trial assessing safety and efficacy of eculizumab in refractory generalized myasthenia gravis has completed with results posted in 2…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2010-07-30Clinical Trial Update: Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis [Phase 3]
A Phase 3 efficacy and safety trial of GB-0998 for generalized myasthenia gravis has completed.